January 31, 2012 — Is the policy for the human papillomavirus (HPV) vaccine at odds with evidence-based medicine?
Yes, according to an essay published online December 22, 2011, in the Annals of Medicine.
Canadian researchers Lucija Tomljenovic, PhD, and Christopher Shaw, PhD, from the Neural Dynamics Research Group, University of British Columbia, in Vancouver, point out that there is a major discrepancy in claims regarding the safety and efficacy of Gardasil (Merck & Co) and Cervarix (GlaxoSmithKline) — the 2 HPV vaccines that are currently on the market.
The vaccines have been heavily promoted in the United States by their respective manufacturers, the essayists report. In addition, the vaccines are backed by government agencies in the United States, including the Center for Disease Control and Prevention and the US Food and Drug Administration, and by medical authorities in a number of other countries.
HPV vaccination has been mired in controversy since the first vaccine was approved in the United States in 2006. There have been clashes among politicians, parents, professional and advocacy organizations, and public health officials, with heated exchanges over issues ranging from safety, the premise that vaccination will promote sexual activity in teens, cost, and concerns about aggressive lobbying by Merck to make the vaccine mandatory for girls.
Drs. Tomljenovic and Shaw note that skepticism about the vaccine has been increasing for a number of reasons, despite reassurances from the public-health sector. In their essay, they examine the current evidence to answer a key question: “Is it possible that HPV vaccines have been promoted to women based on inaccurate information?”
Does it Prevent Cancer?
Read the full article here